HDM1005 vs Tirzepatide (Mounjaro)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline
HDM1005
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07394114 (registry estimate)
No aligned efficacy figure on record for this race.
Tirzepatide (Mounjaro)
Marketed by Eli Lilly and partners
NCT03730662 · Phase 3 · completed
The study randomized 2,002 participants to tirzepatide or active insulin glargine control, but treatment was open-label rather than blinded. The primary endpoint was change in HbA1c, a laboratory surrogate rather than a hard clinical outcome; although the primary comparisons were statistically significant in favor of tirzepatide, this supports a moderate evidence grade.
Next expected readout: December 2027 · NCT06657209 (registry estimate)
Reported efficacy
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579 (met)
Result source: NCT04255433
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | HDM1005 | Tirzepatide (Mounjaro) |
|---|---|---|
| HbA1c, change | —Trial running · NCT07394114 | -2.1% vs 0.0%−2.1 vs placeboNCT0395483450 other results
|
| Body weight, change (kg) | —Trial running · NCT07394114 | -9.5 vs -0.7−8.8 vs placeboNCT0395483437 other results
|
| HbA1c below 7% | —Trial running · NCT07394114 | 87.9% vs 19.6%+68.3 vs placeboNCT0395483436 other results
|
| Fasting plasma glucose, change | —Trial running · NCT07394114 | —Not posted · NCT06534411 |
| 3-point MACE (% with event) | —Trial running · NCT07394114 | 12.2% vs 13.1%vs DulaglutideNCT04255433 |
HbA1c, change
- HDM1005
- —Trial running · NCT07394114
- Tirzepatide (Mounjaro)
- -2.1% vs 0.0%−2.1 vs placeboNCT03954834
50 other results
- -2.6% vs -0.9% NCT04039503
- -2.0% vs -0.8% NCT05963022
- -1.9% vs 0.0% NCT03954834
- -2.6% vs -0.9% NCT04039503
- -1.8% vs -0.8% NCT05963022
- -1.9% vs 0.0% NCT03954834
- -2.2% vs -0.8% NCT05963022
- -2.6% vs -1.4% NCT03730662
- -2.4% vs -1.3% NCT03882970
- -2.8% vs -1.3% NCT03861052
- -2.5% vs -1.9% NCT03987919
- -2.5% vs -0.9% NCT04093752
- -2.4% vs -1.4% NCT03730662
- -2.2% vs -1.3% NCT03882970
- -2.5% vs -1.3% NCT03861052
- -2.4% vs -1.9% NCT03987919
- -2.4% vs -0.9% NCT04093752
- -2.4% vs -1.3% NCT03861052
- -2.2% vs -0.9% NCT04039503
- -2.2% vs -0.2% NCT05260021
- -1.9% vs -0.2% NCT05260021
- -1.7% vs -0.9% NCT04255433
- -2.5% vs -1.2% NCT04537923
- -2.3% vs -1.2% NCT04537923
- -2.2% vs -1.4% NCT03730662
- -1.9% vs -1.3% NCT03882970
- -2.0% vs -1.2% NCT04537923
- -2.1% vs -1.9% NCT03987919
- -2.2% vs -0.9% NCT04093752
- -1.9% vs -0.1% NCT03131687
- -2% vs 0.2% NCT03311724
- -1.8% vs 0.2% NCT03311724
- -1.9% vs -0.1% NCT03131687
- -1.7% vs -0.1% NCT03131687
- -1.7% vs 0.2% NCT03311724
- -1.1% vs -0.1% NCT03131687
- -1.6% vs -0.7% NCT05564039
- 2.0% vs 0.3% NCT03951753
- -2.4% vs 0.1% NCT03131687
- -1.7% vs -0.1% NCT03131687
- -2.1% vs -0.1% NCT03131687
- -2% vs 0.1% NCT03131687
- -1.7% vs -0.1% NCT03131687
- -2% vs -0.1% NCT03131687
- -1.6% vs 0.1% NCT03131687
- -1.5% vs -0.1% NCT03131687
- -1.7% vs -0.1% NCT03131687
- -0.7% vs 0.1% NCT03131687
- -0.9% vs -0.1% NCT03131687
- -0.9% vs -0.1% NCT03131687
Body weight, change (kg)
- HDM1005
- —Trial running · NCT07394114
- Tirzepatide (Mounjaro)
- -9.5 vs -0.7−8.8 vs placeboNCT03954834
37 other results
- -10.9 vs 1.7 NCT04039503
- -8.7 vs -1.3 NCT05963022
- -4.3 vs 1.7 NCT05691712
- -7.8 vs -0.7 NCT03954834
- -8.2 vs 1.7 NCT04039503
- -5.5 vs -1.3 NCT05963022
- -4.8 vs 1.7 NCT05691712
- -7 vs -0.7 NCT03954834
- -6.2 vs 1.7 NCT04039503
- -6.1 vs -1.3 NCT05963022
- -2.7 vs 1.7 NCT05691712
- -11.7 vs 1.9 NCT03730662
- -12.9 vs 2.3 NCT03882970
- -12 vs 3.8 NCT04537923
- -10.7 vs -0.5 NCT03861052
- -12.4 vs -6.2 NCT03987919
- -7.2 vs 1.5 NCT04093752
- -9.5 vs 1.9 NCT03730662
- -10.7 vs 2.3 NCT03882970
- -9.9 vs 3.8 NCT04537923
- -8.5 vs -0.5 NCT03861052
- -10.3 vs -6.2 NCT03987919
- -7 vs 1.5 NCT04093752
- -7.1 vs 1.9 NCT03730662
- -7.5 vs 2.3 NCT03882970
- -6.9 vs 3.8 NCT04537923
- -5.8 vs -0.5 NCT03861052
- -7.8 vs -6.2 NCT03987919
- -5 vs 1.5 NCT04093752
- -11.3 vs -0.4 NCT03131687
- -5.5 vs -0.5 NCT03311724
- -5.7 vs -0.5 NCT03311724
- -8.7 vs -0.4 NCT03131687
- -4.8 vs -0.4 NCT03131687
- -5.3 vs -0.5 NCT03311724
- -0.9 vs -0.4 NCT03131687
- -11 vs -3.6 NCT05564039
HbA1c below 7%
- HDM1005
- —Trial running · NCT07394114
- Tirzepatide (Mounjaro)
- 87.9% vs 19.6%+68.3 vs placeboNCT03954834
36 other results
- 94.0% vs 33.9% NCT04039503
- 83.3% vs 38.3% NCT05963022
- 91.5% vs 19.6% NCT03954834
- 97.3% vs 33.9% NCT04039503
- 86.4% vs 38.3% NCT05963022
- 86.8% vs 19.6% NCT03954834
- 93.0% vs 33.9% NCT04039503
- 84.5% vs 37.4% NCT05260021
- 90.4% vs 38.3% NCT05963022
- 79.6% vs 37.4% NCT05260021
- 90.7% vs 50.7% NCT03730662
- 92.6% vs 61.3% NCT03882970
- 79.9% vs 36.7% NCT04537923
- 99.4% vs 67.3% NCT03861052
- 92.2% vs 81.1% NCT03987919
- 84.4% vs 23.7% NCT04093752
- 88.2% vs 50.7% NCT03730662
- 89.7% vs 61.3% NCT03882970
- 75.6% vs 36.7% NCT04537923
- 96.8% vs 67.3% NCT03861052
- 88.9% vs 81.1% NCT03987919
- 86.0% vs 23.7% NCT04093752
- 81.0% vs 50.7% NCT03730662
- 82.4% vs 61.3% NCT03882970
- 61.0% vs 36.7% NCT04537923
- 93.7% vs 67.3% NCT03861052
- 85.5% vs 81.1% NCT03987919
- 75.4% vs 23.7% NCT04093752
- 77.4% vs 11.8% NCT03131687
- 87% vs 10% NCT03311724
- 84.6% vs 10% NCT03311724
- 90% vs 11.8% NCT03131687
- 69.1% vs 11.8% NCT03131687
- 74.1% vs 10% NCT03311724
- 32.7% vs 11.8% NCT03131687
- 84.2% vs 52.4% NCT05564039
Fasting plasma glucose, change
- HDM1005
- —Trial running · NCT07394114
- Tirzepatide (Mounjaro)
- —Not posted · NCT06534411
3-point MACE (% with event)
- HDM1005
- —Trial running · NCT07394114
- Tirzepatide (Mounjaro)
- 12.2% vs 13.1%vs DulaglutideNCT04255433
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HDM1005: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. HDM1005: 0 of 4 rows · Tirzepatide (Mounjaro): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tirzepatide (Mounjaro) |
|---|---|
| Dropout rate | 2.7%15 mg once weeklya NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 65 more results3.3%10 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.4%5 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 10.1%15 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.4%10 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 2%5 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 14.9%15 mg NCT03954834 · Phase 3 7.4%10 mg NCT03954834 · Phase 3 5.8%5 mg NCT03954834 · Phase 3 5.1%15 mg weekly NCT03987919 · Phase 3 5.8%10 mg weekly NCT03987919 · Phase 3 4%5 mg weekly NCT03987919 · Phase 3 5.3%15 mg NCT03882970 · Phase 3 11.1%10 mg NCT03882970 · Phase 3 7.2%5 mg NCT03882970 · Phase 3 8.3%15 mg NCT04039503 · Phase 3 3.4%10 mg NCT04039503 · Phase 3 6%5 mg NCT04039503 · Phase 3 —10 mg NCT05260021 · Phase 3 —10 mg NCT05260021 · Phase 3 —5 mg NCT05260021 · Phase 3 —5 mg NCT05260021 · Phase 3 —MTD NCT04255433 · Phase 3 —15 mg or MTD NCT05564039 · Phase 4 · registry result, not featured evidence —5 mg NCT05706506 · Phase 4 · registry result, not featured evidence 7.7%15 mg NCT05963022 · Phase 3 · registry result, not featured evidence 9.8%10 mg NCT05963022 · Phase 3 · registry result, not featured evidence —5 mg NCT05963022 · Phase 3 · registry result, not featured evidence 7.9%15 mg NCT05691712 · Phase 3 · registry result, not featured evidence 7.7%10 mg NCT05691712 · Phase 3 · registry result, not featured evidence —5 mg NCT05691712 · Phase 3 · registry result, not featured evidence 4.7%15 mg NCT04537923 · Phase 3 · registry result, not featured evidence 4.2%10 mg NCT04537923 · Phase 3 · registry result, not featured evidence 6.2%5 mg NCT04537923 · Phase 3 · registry result, not featured evidence 12.7%15 mg NCT04093752 · Phase 3 · registry result, not featured evidence 11.8%10 mg NCT04093752 · Phase 3 · registry result, not featured evidence 7.4%5 mg NCT04093752 · Phase 3 · registry result, not featured evidence 3.1%15 mg NCT03861052 · Phase 3 · registry result, not featured evidence 4.4%10 mg NCT03861052 · Phase 3 · registry result, not featured evidence 2.5%5 mg NCT03861052 · Phase 3 · registry result, not featured evidence 15.1%15 mg NCT03131687 · Phase 2 · registry result, not featured evidence —15 mg NCT03131687 · Phase 2 · registry result, not featured evidence 7.7%10 mg NCT03131687 · Phase 2 · registry result, not featured evidence 5.5%5 mg NCT03131687 · Phase 2 · registry result, not featured evidence 17%1 mg NCT03131687 · Phase 2 · registry result, not featured evidence 7.1%2.5, 5, 10, and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence 3.6%2.5, 7.5 and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence 3.4%4, 8 and 12mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence —15 mg NCT04050553 · Phase 1 · registry result, not featured evidence 0%2.5 to 15 mg NCT04235959 · Phase 1 · registry result, not featured evidence 10%2.5 to 10 mg NCT04235959 · Phase 1 · registry result, not featured evidence 8.9%15 mg NCT03951753 · Phase 1 · registry result, not featured evidence 0%5 mg NCT03322631 · Phase 1 · registry result, not featured evidence 6.3%5 mg/10 mg/15 mg NCT03322631 · Phase 1 · registry result, not featured evidence 8.3%2.5 mg/5 mg/10 mg NCT03322631 · Phase 1 · registry result, not featured evidence —5mg NCT02759107 · Phase 1 · registry result, not featured evidence —5mg NCT02759107 · Phase 1 · registry result, not featured evidence —8mg NCT02759107 · Phase 1 · registry result, not featured evidence —4.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —2.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —1.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —1mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.25mg NCT02759107 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 0%15 mg once weeklya NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 65 more results0.6%10 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.9%5 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.4%15 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.4%10 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.4%5 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%15 mg NCT03954834 · Phase 3 2.5%10 mg NCT03954834 · Phase 3 0.8%5 mg NCT03954834 · Phase 3 0.2%15 mg weekly NCT03987919 · Phase 3 0.9%10 mg weekly NCT03987919 · Phase 3 0.2%5 mg weekly NCT03987919 · Phase 3 0.8%15 mg NCT03882970 · Phase 3 1.9%10 mg NCT03882970 · Phase 3 1.4%5 mg NCT03882970 · Phase 3 1.7%15 mg NCT04039503 · Phase 3 0%10 mg NCT04039503 · Phase 3 2.6%5 mg NCT04039503 · Phase 3 —10 mg NCT05260021 · Phase 3 —10 mg NCT05260021 · Phase 3 —5 mg NCT05260021 · Phase 3 —5 mg NCT05260021 · Phase 3 —MTD NCT04255433 · Phase 3 —15 mg or MTD NCT05564039 · Phase 4 · registry result, not featured evidence —5 mg NCT05706506 · Phase 4 · registry result, not featured evidence 1.9%15 mg NCT05963022 · Phase 3 · registry result, not featured evidence 2%10 mg NCT05963022 · Phase 3 · registry result, not featured evidence —5 mg NCT05963022 · Phase 3 · registry result, not featured evidence 3.2%15 mg NCT05691712 · Phase 3 · registry result, not featured evidence 1.5%10 mg NCT05691712 · Phase 3 · registry result, not featured evidence —5 mg NCT05691712 · Phase 3 · registry result, not featured evidence 0.8%15 mg NCT04537923 · Phase 3 · registry result, not featured evidence 0.4%10 mg NCT04537923 · Phase 3 · registry result, not featured evidence 0.8%5 mg NCT04537923 · Phase 3 · registry result, not featured evidence 8.3%15 mg NCT04093752 · Phase 3 · registry result, not featured evidence 8.3%10 mg NCT04093752 · Phase 3 · registry result, not featured evidence 3%5 mg NCT04093752 · Phase 3 · registry result, not featured evidence 1.3%15 mg NCT03861052 · Phase 3 · registry result, not featured evidence 0.6%10 mg NCT03861052 · Phase 3 · registry result, not featured evidence 0.6%5 mg NCT03861052 · Phase 3 · registry result, not featured evidence 3.8%15 mg NCT03131687 · Phase 2 · registry result, not featured evidence —15 mg NCT03131687 · Phase 2 · registry result, not featured evidence 1.9%10 mg NCT03131687 · Phase 2 · registry result, not featured evidence 0%5 mg NCT03131687 · Phase 2 · registry result, not featured evidence 1.9%1 mg NCT03131687 · Phase 2 · registry result, not featured evidence —2.5, 5, 10, and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence —2.5, 7.5 and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence —4, 8 and 12mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence —15 mg NCT04050553 · Phase 1 · registry result, not featured evidence 0%2.5 to 15 mg NCT04235959 · Phase 1 · registry result, not featured evidence 0%2.5 to 10 mg NCT04235959 · Phase 1 · registry result, not featured evidence 2.2%15 mg NCT03951753 · Phase 1 · registry result, not featured evidence 0%5 mg NCT03322631 · Phase 1 · registry result, not featured evidence 6.3%5 mg/10 mg/15 mg NCT03322631 · Phase 1 · registry result, not featured evidence 0%2.5 mg/5 mg/10 mg NCT03322631 · Phase 1 · registry result, not featured evidence —5mg NCT02759107 · Phase 1 · registry result, not featured evidence —5mg NCT02759107 · Phase 1 · registry result, not featured evidence —8mg NCT02759107 · Phase 1 · registry result, not featured evidence —4.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —2.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —1.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —1mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence —0.25mg NCT02759107 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 12.1%15 mg once weeklya NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 65 more results16.5%10 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 14.6%5 mg once weekly NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.4%15 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.5%10 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.4%5 mg NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%15 mg NCT03954834 · Phase 3 1.7%10 mg NCT03954834 · Phase 3 4.1%5 mg NCT03954834 · Phase 3 5.7%15 mg weekly NCT03987919 · Phase 3 5.3%10 mg weekly NCT03987919 · Phase 3 7%5 mg weekly NCT03987919 · Phase 3 7.2%15 mg NCT03882970 · Phase 3 5.6%10 mg NCT03882970 · Phase 3 8.1%5 mg NCT03882970 · Phase 3 7.5%15 mg NCT04039503 · Phase 3 10.9%10 mg NCT04039503 · Phase 3 7.8%5 mg NCT04039503 · Phase 3 3%10 mg NCT05260021 · Phase 3 3%10 mg NCT05260021 · Phase 3 3.1%5 mg NCT05260021 · Phase 3 3.1%5 mg NCT05260021 · Phase 3 31.8%MTD NCT04255433 · Phase 3 7.2%15 mg or MTD NCT05564039 · Phase 4 · registry result, not featured evidence 0.7%5 mg NCT05706506 · Phase 4 · registry result, not featured evidence 5.8%15 mg NCT05963022 · Phase 3 · registry result, not featured evidence 11.8%10 mg NCT05963022 · Phase 3 · registry result, not featured evidence 9.6%5 mg NCT05963022 · Phase 3 · registry result, not featured evidence 12.7%15 mg NCT05691712 · Phase 3 · registry result, not featured evidence 7.7%10 mg NCT05691712 · Phase 3 · registry result, not featured evidence 12.3%5 mg NCT05691712 · Phase 3 · registry result, not featured evidence 7.2%15 mg NCT04537923 · Phase 3 · registry result, not featured evidence 6.7%10 mg NCT04537923 · Phase 3 · registry result, not featured evidence 8.2%5 mg NCT04537923 · Phase 3 · registry result, not featured evidence 6.6%15 mg NCT04093752 · Phase 3 · registry result, not featured evidence 6.1%10 mg NCT04093752 · Phase 3 · registry result, not featured evidence 6.5%5 mg NCT04093752 · Phase 3 · registry result, not featured evidence 4.4%15 mg NCT03861052 · Phase 3 · registry result, not featured evidence 6.3%10 mg NCT03861052 · Phase 3 · registry result, not featured evidence 5%5 mg NCT03861052 · Phase 3 · registry result, not featured evidence —15 mg NCT03131687 · Phase 2 · registry result, not featured evidence 3.8%15 mg NCT03131687 · Phase 2 · registry result, not featured evidence 5.9%10 mg NCT03131687 · Phase 2 · registry result, not featured evidence 1.8%5 mg NCT03131687 · Phase 2 · registry result, not featured evidence 3.8%1 mg NCT03131687 · Phase 2 · registry result, not featured evidence 0%2.5, 5, 10, and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence 0%2.5, 7.5 and 15mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence 3.4%4, 8 and 12mg Tirzepatide NCT03311724 · Phase 2 · registry result, not featured evidence 10.3%15 mg NCT04050553 · Phase 1 · registry result, not featured evidence 0%2.5 to 15 mg NCT04235959 · Phase 1 · registry result, not featured evidence 0%2.5 to 10 mg NCT04235959 · Phase 1 · registry result, not featured evidence 2.2%15 mg NCT03951753 · Phase 1 · registry result, not featured evidence 0%5 mg NCT03322631 · Phase 1 · registry result, not featured evidence 0%5 mg/10 mg/15 mg NCT03322631 · Phase 1 · registry result, not featured evidence 0%2.5 mg/5 mg/10 mg NCT03322631 · Phase 1 · registry result, not featured evidence 0%5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%8mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%4.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%2.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%1.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%1mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%0.5mg NCT02759107 · Phase 1 · registry result, not featured evidence 0%0.25mg NCT02759107 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 15 mg once weeklya nausea 22.5% diarrhoea 21.9% decreased appetite 10.4% NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 63 more results10 mg once weekly diarrhoea 19.8% nausea 16.2% decreased appetite 11% NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg once weekly diarrhoea 12.5% nausea 11.9% decreased appetite 8.8% NCT03730662 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15 mg nausea 27% nasopharyngitis 18.2% constipation 14.9% NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg constipation 13.6% diarrhoea 13.6% nasopharyngitis 13.6% NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg nasopharyngitis 18.9% nausea 9.5% constipation 8.1% NCT03861039 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg nausea 18.2% (placebo 6.1%) diarrhoea 11.6% (placebo 7.8%) decreased appetite 8.3% (placebo 0.9%) NCT03954834 · Phase 3 10 mg diarrhoea 14% (placebo 7.8%) nausea 13.2% (placebo 6.1%) decreased appetite 6.6% (placebo 0.9%) NCT03954834 · Phase 3 5 mg diarrhoea 11.6% (placebo 7.8%) nausea 11.6% (placebo 6.1%) dyspepsia 9.1% (placebo 3.5%) NCT03954834 · Phase 3 15 mg diarrhoea 20.8% (placebo 10%) nausea 18.3% (placebo 2.5%) decreased appetite 14.2% (placebo 1.7%) NCT04039503 · Phase 3 10 mg nausea 17.6% (placebo 2.5%) decreased appetite 12.6% (placebo 1.7%) diarrhoea 12.6% (placebo 10%) NCT04039503 · Phase 3 5 mg nasopharyngitis 15.5% (placebo 19.2%) nausea 12.9% (placebo 2.5%) diarrhoea 12.1% (placebo 10%) NCT04039503 · Phase 3 10 mg nasopharyngitis 9.1% (placebo 5.9%) vomiting 6.1% (placebo 2.9%) diarrhoea 3% (placebo 5.9%) NCT05260021 · Phase 3 10 mg diarrhoea 24.2% (placebo 5.9%) nausea 18.2% (placebo 8.8%) abdominal pain upper 12.1% (placebo 8.8%) NCT05260021 · Phase 3 5 mg diarrhoea 25% (placebo 5.9%) nausea 21.9% (placebo 8.8%) abdominal pain 15.6% (placebo 2.9%) NCT05260021 · Phase 3 5 mg diarrhoea 15.6% (placebo 5.9%) dysmenorrhoea 9.5% (placebo 0%) headache 9.4% (placebo 2.9%) NCT05260021 · Phase 3 15 mg or MTD nausea 25.2% diarrhoea 22.3% nasopharyngitis 10.1% NCT05564039 · Phase 4 · registry result, not featured evidence 15 mg diarrhoea 28.8% (placebo 0%) decreased appetite 26.9% (placebo 0%) nausea 26.9% (placebo 2%) NCT05963022 · Phase 3 · registry result, not featured evidence 10 mg decreased appetite 25.5% (placebo 0%) diarrhoea 23.5% (placebo 0%) nausea 21.6% (placebo 2%) NCT05963022 · Phase 3 · registry result, not featured evidence 5 mg decreased appetite 28.8% (placebo 0%) diarrhoea 23.1% (placebo 0%) upper respiratory tract infection 21.2% (placebo 19.6%) NCT05963022 · Phase 3 · registry result, not featured evidence 15 mg diarrhoea 36.5% (placebo 7.8%) decreased appetite 31.7% (placebo 0%) upper respiratory tract infection 17.5% (placebo 14.1%) NCT05691712 · Phase 3 · registry result, not featured evidence 10 mg diarrhoea 36.9% (placebo 7.8%) decreased appetite 24.6% (placebo 0%) lipase increased 21.5% (placebo 3.1%) NCT05691712 · Phase 3 · registry result, not featured evidence 5 mg decreased appetite 29.2% (placebo 0%) diarrhoea 26.2% (placebo 7.8%) upper respiratory tract infection 20% (placebo 14.1%) NCT05691712 · Phase 3 · registry result, not featured evidence 15 mg nausea 25.8% decreased appetite 16.9% vomiting 12.7% NCT04537923 · Phase 3 · registry result, not featured evidence 10 mg nausea 20.6% diarrhoea 15.1% decreased appetite 11.8% NCT04537923 · Phase 3 · registry result, not featured evidence 5 mg nausea 13.6% diarrhoea 11.9% covid-19 11.5% NCT04537923 · Phase 3 · registry result, not featured evidence 15 mg decreased appetite 44.5% diarrhoea 44.1% nausea 31.9% NCT04093752 · Phase 3 · registry result, not featured evidence 10 mg decreased appetite 47.8% diarrhoea 45.2% nausea 32.9% NCT04093752 · Phase 3 · registry result, not featured evidence 5 mg diarrhoea 33.5% decreased appetite 32.2% nausea 20% NCT04093752 · Phase 3 · registry result, not featured evidence 15 mg decreased appetite 21.9% nausea 20% constipation 13.8% NCT03861052 · Phase 3 · registry result, not featured evidence 10 mg nausea 19.6% constipation 17.7% nasopharyngitis 15.8% NCT03861052 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 18.2% diarrhoea 17% constipation 15.1% NCT03861052 · Phase 3 · registry result, not featured evidence 15 mg nausea 39.6% (placebo 5.9%) diarrhoea 32.1% (placebo 3.9%) vomiting 26.4% (placebo 2%) NCT03131687 · Phase 2 · registry result, not featured evidence 10 mg decreased appetite 25.5% (placebo 2%) diarrhoea 23.5% (placebo 3.9%) nausea 21.6% (placebo 5.9%) NCT03131687 · Phase 2 · registry result, not featured evidence 5 mg diarrhoea 23.6% (placebo 3.9%) decreased appetite 20% (placebo 2%) nausea 20% (placebo 5.9%) NCT03131687 · Phase 2 · registry result, not featured evidence 1 mg diarrhoea 13.5% (placebo 3.9%) dizziness 7.7% (placebo 3.9%) decreased appetite 3.8% (placebo 2%) NCT03131687 · Phase 2 · registry result, not featured evidence nausea 39.3% (placebo 7.7%) diarrhoea 35.7% (placebo 7.7%) decreased appetite 21.4% (placebo 0%) NCT03311724 · Phase 2 · registry result, not featured evidence nausea 35.7% (placebo 7.7%) diarrhoea 32.1% (placebo 7.7%) decreased appetite 28.6% (placebo 0%) NCT03311724 · Phase 2 · registry result, not featured evidence diarrhoea 31% (placebo 7.7%) nausea 24.1% (placebo 7.7%) dyspepsia 17.2% (placebo 0%) NCT03311724 · Phase 2 · registry result, not featured evidence 15 mg nausea 38.5% (placebo 5.6%) diarrhoea 17.9% (placebo 11.1%) headache 17.9% (placebo 8.3%) NCT04050553 · Phase 1 · registry result, not featured evidence 2.5 to 15 mg decreased appetite 80% (placebo 0%) abdominal distension 50% (placebo 0%) diarrhoea 40% (placebo 0%) NCT04235959 · Phase 1 · registry result, not featured evidence 2.5 to 10 mg diarrhoea 60% (placebo 0%) decreased appetite 50% (placebo 0%) hyperlipidaemia 50% (placebo 75%) NCT04235959 · Phase 1 · registry result, not featured evidence 15 mg decreased appetite 60% (placebo 25%) early satiety 35.6% (placebo 21.4%) injection site haematoma 26.7% (placebo 42.9%) NCT03951753 · Phase 1 · registry result, not featured evidence 5 mg decreased appetite 45.5% (placebo 0%) abdominal distension 27.3% (placebo 11.1%) malaise 9.1% (placebo 0%) NCT03322631 · Phase 1 · registry result, not featured evidence 5 mg/10 mg/15 mg decreased appetite 62.5% (placebo 0%) constipation 50% (placebo 11.1%) diarrhoea 31.3% (placebo 0%) NCT03322631 · Phase 1 · registry result, not featured evidence 2.5 mg/5 mg/10 mg constipation 66.7% (placebo 11.1%) decreased appetite 50% (placebo 0%) diarrhoea 25% (placebo 0%) NCT03322631 · Phase 1 · registry result, not featured evidence 5mg decreased appetite 66.7% (placebo 7.1%) abdominal distension 50% (placebo 7.1%) catheter site erythema 33.3% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence 5mg decreased appetite 66.7% (placebo 7.1%) abdominal distension 11.1% (placebo 7.1%) catheter site bruise 11.1% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence 8mg decreased appetite 85.7% (placebo 7.1%) nausea 57.1% (placebo 0%) vomiting 42.9% (placebo 0%) NCT02759107 · Phase 1 · registry result, not featured evidence 4.5mg decreased appetite 83.3% (placebo 7.1%) abdominal distension 66.7% (placebo 7.1%) dizziness 33.3% (placebo 0%) NCT02759107 · Phase 1 · registry result, not featured evidence 2.5mg abdominal distension 16.7% (placebo 7.1%) catheter site erythema 16.7% (placebo 7.1%) nausea 16.7% (placebo 0%) NCT02759107 · Phase 1 · registry result, not featured evidence 1.5mg catheter site erythema 16.7% (placebo 7.1%) cough 16.7% (placebo 0%) decreased appetite 16.7% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence 1mg application site erythema 20% (placebo 0%) catheter site bruise 20% (placebo 7.1%) dermatitis contact 20% (placebo 0%) NCT02759107 · Phase 1 · registry result, not featured evidence 0.5mg upper respiratory tract infection 33.3% (placebo 14.3%) vessel puncture site bruise 33.3% (placebo 0%) injection site pain 25% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence 0.5mg application site erythema 33.3% (placebo 0%) medical device site pruritus 33.3% (placebo 0%) abdominal distension 16.7% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence 0.5mg decreased appetite 22.2% (placebo 7.1%) upper respiratory tract infection 22.2% (placebo 14.3%) hysterectomy 16.7% (placebo 0%) NCT02759107 · Phase 1 · registry result, not featured evidence 0.25mg catheter site bruise 16.7% (placebo 7.1%) catheter site swelling 16.7% (placebo 7.1%) injection site pain 16.7% (placebo 7.1%) NCT02759107 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 60 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tirzepatide (Mounjaro)
show 50 more results
show 37 more results
show 36 more results
show 3 more results
show 14 more results
show 3 more results
show 2 more results
show 3 more results
show 3 more results
show 2 more results
show 28 more results
show 20 more results
+ 46 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDM1005's landscape · Tirzepatide (Mounjaro)'s landscape